These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31883056)

  • 1. A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration.
    Sharma S; Khan M; Chaturvedi A;
    Ophthalmol Ther; 2020 Mar; 9(1):103-114. PubMed ID: 31883056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.
    Sharma S; ; Khan M; Chaturvedi A
    Ophthalmol Ther; 2020 Sep; 9(3):625-639. PubMed ID: 32617913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
    Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
    Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.
    Sharma S; Khan MA; Chaturvedi A;
    Ophthalmologica; 2019; 241(1):24-31. PubMed ID: 29945143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
    Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
    Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence.
    Kelkar AS; Kelkar J; Bolisetty M; Kelkar SB
    Indian J Ophthalmol; 2021 Jun; 69(6):1469-1474. PubMed ID: 34011722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence.
    Chakraborty D; Mondal S; Boral S; Das A; Sinha TK; Majumdar S; Bhattacharya R; Maitra R
    Clin Ophthalmol; 2023; 17():1067-1076. PubMed ID: 37064960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.
    Soman M; Nair I; Sheth JU; Nair U
    Ophthalmol Ther; 2022 Jun; 11(3):1175-1186. PubMed ID: 35412266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
    Regillo CD; Busbee BG; Ho AC; Ding B; Haskova Z
    Am J Ophthalmol; 2015 Nov; 160(5):1014-1023.e2. PubMed ID: 26231305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
    Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K;
    Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
    Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
    BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab.
    Unsal E; Cubuk MO
    J Curr Ophthalmol; 2018 Dec; 30(4):337-342. PubMed ID: 30555967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Hamid MA; Abdelfattah NS; Salamzadeh J; Abdelaziz STA; Sabry AM; Mourad KM; Shehab AA; Kuppermann BD
    Int J Retina Vitreous; 2021 Apr; 7(1):26. PubMed ID: 33795022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic.
    Stepanov A; Nemcansky J; Veith M; Manethova K; Stredova M; Pencak M; Tarkova A; Studnicka J
    Eur J Ophthalmol; 2021 Sep; 31(5):2488-2495. PubMed ID: 33198503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K; Prünte C
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.